MULTIPLE MYELOMA

Latest News

Ciltacabtagene Autoleucel Produces Deep, Durable Responses in Multiple Myeloma
Ciltacabtagene Autoleucel Produces Deep, Durable Responses in Multiple Myeloma

February 23rd 2024

In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.

Utilization Challenges Hold Back the Adoption of Bispecific Therapies
Utilization Challenges Hold Back the Adoption of Bispecific Therapies

February 23rd 2024

Linvoseltamab Earns FDA Priority Review for Multiple Myeloma
Linvoseltamab Earns FDA Priority Review for Multiple Myeloma

February 22nd 2024

FDA Approves sBLA for Reduced Teclistamab Dose in R/R Multiple Myeloma
FDA Approves sBLA for Reduced Teclistamab Dose in R/R Multiple Myeloma

February 21st 2024

Targeting GPRC5D Impacts Survival of Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
Targeting GPRC5D Impacts Survival of Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

February 7th 2024

Video Series
Video Interviews
Podcasts

More News